| Metric | Value (₹ Cr) | Q3 FY26 | Q4 FY25 |
|---|---|---|---|
| Revenue | 210.41 | 31.6% | 27.2% |
| Total Income | 213.06 | 32.4% | 27.3% |
| Expenditure | 201.81 | 37.4% | 26.0% |
| PBT | 11.25 | 19.7% | 54.8% |
| Net Profit | 10.78 | 2.9% | 79.6% |
| OPM | 12.47% | 3.37pp | 3.23pp |
| NPM | 5.06% | 1.45pp | 1.47pp |
| EPS | 19.70 | 0.9% | 55.0% |
Fredun Pharma FY26: Revenue Up 40%, EBITDA Surges 72%
25 May 2026 · 25 May, 6:02 pm
Summary
Fredun Pharmaceuticals Limited delivered a robust performance for FY26, with total income jumping 40.08% year-on-year to ₹639.12 Cr. This growth was accompanied by a significant 72.05% surge in EBITDA to ₹94.79 Cr, with margins expanding to 14.83%. Net Profit also saw substantial growth, rising 59.59% to ₹33.21 Cr for the full year. Management highlighted the steady progress in building a diversified and resilient business, with growth coming across multiple segments and increased investments in future growth avenues like the launch of a premium hormone therapy range and the DAULCÉL platform, alongside facility expansion.
Key Highlights
- 1
Fredun Pharmaceuticals Limited reported a robust FY26 performance with total income scaling to ₹639.12 Cr, marking a 40.08% year-on-year increase.
- 2
For FY26, EBITDA surged by 72.05% to ₹94.79 Cr, while EBITDA margins expanded to 14.83%, indicating strong operational leverage.
- 3
Net Profit for FY26 grew by 59.59% to ₹33.21 Cr, significantly outpacing revenue growth and demonstrating improving business quality.
- 4
In Q4 FY26, total income stood at ₹213.05 Cr, up 27.27% year-on-year, with EBITDA increasing by 67.05% and Net Profit by 56.47%.
- 5
The Board recommended a dividend of ₹0.70 per share for eligible shareholders.
- 6
A bonus share issue in the ratio of 2:1, meaning 2 fully paid-up equity shares for every 1 existing share, was recommended by the Board, subject to shareholder approval.
- 7
Infomerics upgraded the company's credit rating to IVR BBB+ (Stable) from IVR BBB (Stable), strengthening banking confidence and institutional credibility.
Management Comments
Fredun Medhora
FY26 reflects the steady progress we have made in building a diversified and resilient business. Our growth is coming across segments, with continued strength in generics complemented by increasing traction in nutraceuticals, cosmeceuticals, and pet care. This balanced mix is helping us scale more sustainably and reduce dependence on any single segment. The improvement is clearly visible in our performance, with revenue reaching ₹639 crore and margins strengthening during the year. At the same time, we have started investing in the next phase of growth. The launch of our premium hormone therapy range and the DAULCÉL platform marks our entry into more specialized, wellness and preventive healthcare segments. These are early steps, but they open up new avenues beyond our traditional business. Alongside this, the expansion of our Palghar facility and the upgrade in our credit rating to IVR BBB+ give us the capacity and financial strength to support future growth. Going forward, our focus will be on continuing to build across segments while gradually increasing the share of differentiated and higher value products. With multiple growth drivers now in place and a stronger base established, we are confident of sustaining this momentum and delivering consistent growth in the years ahead.
Informational and educational content only. Not investment advice.